Skip to main content

Advertisement

Fig. 8 | Journal of Neuroinflammation

Fig. 8

From: Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway

Fig. 8

a The neutralized statin-Dex were analyzed by flow cytometry. Statin-Dex were incubated with purified Hamster anti-Mouse and rat FasL blocking (0.1, 1, and 10 μg/ml) or purified Hamster IgG3, κ isotype control antibodies (10 μg/ml). In the presence of anti-FasL blocking antibody (final concentration 10 μg/ml), the level of FasL expressed on statin-Dex were significantly decreased. The results are expressed as mean ± SD (*p < 0.05). b Effects of statin-Dex blocked with anti-FasL antibody on the development of EAMG in Lewis rats. Statin-Dex blocked with anti-FasL or isotype antibodies were transferred into EAMG rats via tail vein injection at dose of 10 μg/rat on days 5 and 16 p.i., respectively. The rats in statin-Dex with anti-FasL blocking antibody group exhibited higher clinical scores when compared with rats in statin-Dex with isotype control antibody group (*p < 0.05 and **p < 0.01). The data are expressed as mean ± SD (n = 6 rats per group)

Back to article page